New drug duo shows early promise against advanced cancers
NCT ID NCT05021120
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for signs that the tumours shrank or stopped growing. The study is now complete, and results will help decide if further testing is warranted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ashford Cancer Centre Research
Adelaide, Australia
-
Austin Health
Melbourne, Australia
-
Monash Health
Melbourne, Australia
-
Southside Cancer Care Centre
Sydney, Australia
-
The Kinghorn Cancer Centre, St Vincents Hospital Sydney
Sydney, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?